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Abstract 
Background: The number of lymph nodes (LN) retrieved could be an important 
prognostic factor in gastric cancer. Currently, the established cut-off for 
adequate staging is 15 LN, however this seems not always appropriate to 
improve survival. The aim of our study is to evaluate the effect of the number of 
LN harvested on gastric cancer prognosis. 
Patients and methods: A retrospective analysis of a prospective database with 
476 gastric cancer cases submitted to curative intent surgery, between January 
2010 and December 2015, in an Upper GI Surgery Unit. We analyzed 288 
patients that met the inclusion criteria for this study. Overall survival (OS), 
disease specific survival (DSS) and disease free survival (DFS) curves 
according to the number of LN retrieved were calculated and adjusted to 
pathological stage, type of tumor (EGC vs advanced) and pN. 
Results: Most patients (86,1%) had more than 15 lymph nodes retrieved. 
Harvesting more than 15 LN had positive effects on the OS of patients with 
pStage I tumors, early gastric cancer and pN negative tumors. Retrieving more 
than 15 LN contributed to improvements in DSS and DFS of patients with 
pStage II. When more than 30 LN were retrieved the OS of gastric cancer 
patients was significantly better not only in pStage I tumors, early gastric cancer 
and pN-, but also in pStage III. Harvesting more than 30 LN was also 
associated with better DSS and DFS in pStage II gastric cancer patients. The 
number of LN retrieved was not associated with more morbidity, but slightly 
increased the surgery duration. The independent predictors for the number of 
LN retrieved were type of resection, type of lymphadenectomy, tumor location 
and number of LN invaded. 
Conclusions: The number of LN harvested appears to have prognostic impact 
on gastric cancer survival and lymphadenectomy extension should be 
individually designed for each patient according to tumor stage. 
Keywords 
Gastric cancer, lymph nodes retrieved, prognosis, recurrence, TNM stage 
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Introduction 
Gastric cancer is the fourth most frequent cancer in the world, with 
approximately one million people newly diagnosed per year, and the second 
leading cause of cancer-related death both in men and women [1]. It is 
particularly common in Asian countries where almost 75% of the cases occur. 
Despite a substantially decline of gastric cancer incidence and mortality 
worldwide, Portugal is still one of the European countries with highest mortality 
rates, perhaps as a result of the high prevalence of Helicobacter pylori infection 
[2]. 
Surgical resection combined with appropriate lymphadenectomy is the main 
treatment for patients with gastric cancer [3, 4]. Many features influence the 
prognosis after surgery. Besides depth of invasion, the number of lymph nodes 
(LN) metastasis is the most important prognostic factor for gastric cancer and 
has been considered a staging parameter in the Union for International Cancer 
Control/ American Joint Committee on Cancer (UICC/AJCC) [5, 6]. The 
examination of at least 15 lymph nodes has been traditionally recommended by 
AJCC to optimize staging, however the ideal number of LN that need to be 
examined in order to achieve a reliable staging for the strongest prognostic 
value is not certain [4-7]. 
The proper extent of lymphadenectomy during gastric cancer surgery has been 
the subject of a long discussion.  In Asia, D2 lymphadenectomy has been 
considered the gold standard with improvements in the long-term survival rates 
[7]. Recently the Dutch trial also demonstrate that D2 dissection (without routine 
pancreatectomy and splenectomy) is associated with lower locoregional 
recurrence and disease-related death when compared to D1 lymphadenectomy 
[8]. It seems logical that a more extensive node dissection will harvest more LN 
to be examined pathologically, consequently increasing the staging accuracy 
[7]. However, the contribution of a higher number of LN harvested in the 
improvement of local regional disease control and survival has not been 
consistently established [7].  
Recently the notion that negative lymph nodes (NLN) counts as a possible 
prognostic factor in gastric cancer is emerging. Although patients with NLN 
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gastric cancer have a superior overall survival rate when compared to patients 
with positive LN, some will have recurrence and 15% will die of the disease [9, 
10]. However, little is known about the optimal number of examined LN in 
patients with NLN gastric cancer. 
The aim of this study is to evaluate if the number of LN harvested during 
surgery of gastric cancer patients is related with better long-term survival rates 
in patients with positive LN and NLN, if the threshold of 15 LN required by the 
AJCC remains appropriate and if patients with different TNM stage would 
benefit from a different number of retrieved LN. 
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Patients and methods 
Patient sample 
This study retrospectively analyzed a prospective database of gastric cancer 
patients (n=476), who underwent surgical treatment in Upper GI Surgery Unit of 
Centro Hospitalar de São João – Faculty of Medicine, University of Porto (Porto, 
Portugal), between January 2010 and December 2015. The Institutional Review 
Board approved this study (CES 60-16). 
Patients were selected from the database according to the following criteria: 
gastric adenocarcinoma and curative intent surgery. The exclusion criteria were: 
non-resectional surgery, palliative, pathological stage IV carcinomas, 
prophylactic and completion gastrectomies, atypical resections, other histologic 
types than adenocarcinoma and R2 resections. Patients lost for follow-up were 
not included in this analysis. After screening patients with the above criteria, a 
total of 288 cases were obtained (Figure 1). 
 
Data collection 
With the purpose of characterizing the population the following parameters were 
collected from each patient: age at time of surgery, gender, presence of 
comorbidities, American Society of Anesthesiologists (ASA) physical status 
classification and body mass index (BMI) score. In order to describe the 
clinicopathological profile: tumor location and size (cm), macroscopic 
appearance, histologic type (Laurén classification), growth pattern (Ming 
classification), TNM staging (7th edition, 2010), LN ratio and venous, perineural 
and lymphatic invasions were evaluated.  The surgery approach, type of 
resection and lymphadenectomy and the presence of neoadjuvant therapy were 
used to characterize the therapeutic approach. 
For short-term complications analysis, the following parameters were evaluated: 
post-operative morbidity (less than 30 days after surgery), including 
anastomotic leakage rate and Clavien-Dindo classification (specifically the need 
for intervention, Clavien ≥ IIIa), post-operative mortality, re-intervention, 
transfusion and readmission rates.  Long-term complications (more than 30 
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days after surgery) presence and need for re-intervention were assessed. Some 
perioperative outcomes were categorized: surgery duration (minutes) and post-
operative length-of-stay (LOS) in days. 
The oncological-related outcomes were: type of resection (R), distance (cm) to 
proximal and distal margin on tumor specimen, number of lymph nodes invaded 
and recurrence rate and type. Resection was defined as curative (R0) when the 
tumor was completely removed with all the margins negative; incomplete 
resection was defined as residual gross disease (R2) or positive surgical 
margins [(R1), tumor less than 1 mm from any margin]. 
Clinical, radiologic, or endoscopic signs of disease were used in order to 
diagnose recurrence. 
In survival analysis, overall survival (OS), disease-specific survival (DSS) and 
disease-free survival (DFS) were assessed. OS was defined as the period 
between the day of surgery and death of patient. Patients who had survived 
until the end of the observation period were censored at their last follow-up visit. 
Death from a cause other than gastric cancer was a censoring event in DSS. 
DFS was considered the period between the end of primary therapy and the 
first evidence of disease recurrence. Patient follow-up was completed in March 
2017 for 100% of the population. Median follow-up was 28 (0-83) months. 
All the data was reviewed by two of the authors (HSS, MF) for identification of 
data entry errors. 
 
Perioperative management and surgical procedure 
All the patients were submitted to upper endoscopy with biopsy and 
computerized tomography (CT) as diagnostic procedures for gastric cancer. 
The tumors were staged according to clinical, radiological (CT) or endoscopic 
(endoscopic ultrasonography) features. Staging laparoscopy was applied when 
considered necessary (mostly in local advanced tumors, when resectability was 
uncertain). 
The preoperative clinical stage was used to select the surgical approach and 
the type of lymphadenectomy. In diffuse and proximally located tumors the 
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surgery performed was total gastrectomy with Roux-en-Y reconstruction. In 
distally located tumors the surgery selected was subtotal distal gastrectomy, 
using Billroth II and sporadically Roux-en-Y reconstructions, due to age and 
comorbidities. The extent of lymphadenectomy was classified based on the third 
version of Japanese Gastric Treatment Guidelines, 2010 (Figure 2). 
In the postoperative period, all patients went to the post-surgical intensive care 
unit for post-operatively early extubation, pain control, vigorous respiratory 
therapy, early mobilization and ambulation. According to clinical evolution, food 
intake was permitted. During the first year after surgery the patients were 
followed up at 3-month intervals, during the second year at 6-month intervals 
and annually afterwards. 
 
Statistical analysis 
Statistical analysis was performed using SPSS® 21.0 for Mac (IBM Co., 
Armonk, NY, USA). 
Normal distribution of continuous variables was assessed by visual analysis of 
histograms, normal Q-Q plots and both Kolmogorov-Smirnov and Shapiro-Wilk 
tests of normality. Student's t-test, non-parametric test Mann-Whitney U and 
Welch's t-test were used to compare means, and chi-square or Fisher's exact 
test were used to compare proportions, as appropriate. Odds ratio (OR) and 
95% confidence intervals (CI) were calculated by logistic regression for the 
complications analysis. Linear regression was used for the analysis of the 
impact of the LN retrieved in surgery duration and for the predictors of the 
number of LN harvested. 
Significance was assumed for p values inferior to 0.05. All p values given are 
results of 2-sided tests. 
Cumulative survival curves for OS, DSS and DFS were calculated by Kaplan-
Meier (KM) method and adjusted to pathological stage, type of gastric cancer 
(early gastric cancer versus advanced gastric cancer) and N stage. Log rank 
test was used to assess differences between groups. Hazard ratio (HR) and 
95% confidence intervals (CI) were calculated by Cox regression and adjusted 
for possible confounders for the survival analysis. In order to define a better cut-
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off for the number of LN retrieved, a new category was created based on the 
median (Figure 3) of the LN harvested in patients with a minimum number for 
an adequate staging (≥15 LN).  
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Results 
Population baseline characteristics 
Population baseline characteristics are described in Table 1. The average age 
at surgery was 66,94 ± 12,234 years and there was a predominance of male 
patients (58%). The mean body mass index was 25,852 ± 3,8102. 
Comorbidities were present in 82,3% of the patients and 84,7% were classified 
as ASA score II or III.  
Most gastric cancers (67,7%) were located in the antrum and presented with a 
mean size of 4,444 ± 2,9584 cm. Based on Laurén classification the most 
frequent histologic type was intestinal (45%), and according to Ming 
classification the most common growth pattern was infiltrative (73,1%). Around 
60% of the cases were advanced gastric cancers. The lymph node ratio was 
superior to 0,2 in 24%. Most patients had stage I cancer (45,1%), followed by 
stage III (31,6%) and stage II (23,3%). The most common surgery approach 
(54,5%) was open gastrectomy and the most frequent type of resection was 
Billroth II distal gastrectomy (54,9%), followed by total gastrectomy (38,2%) and 
Roux-en-Y distal gastrectomy (6,9%). D1+ and D2 lymphadenectomy were 
performed in 75% of the patients. Neoadjuvant therapy was applied in 9% of the 
cases. 
Regarding the survival, mean OS was 52,043 ± 2,122 months. The 1-year, 2-
year and 5-year OS were 81%, 71% and 51%, respectively. The mean DFS 
was 62,702 ± 2,079 months and the 1-year, 2-year and 5-year DFS were 86%, 
77% and 70%, respectively. There were significant differences in OS according 
to pStage (p<0,001), EGC (p<0,001) and pN (p<0,001) (Figure 4). In DFS there 
were also significant differences according to pStage (p<0,001), EGC (p<0,001) 
and pN (p<0,001). 
 
Comparative analysis <15 LN versus ≥15 LN retrieved  
Most patients (86,1%) had ≥15 LN retrieved and only a minority (13,9%) had 
<15 LN retrieved. The patients were grouped by the number of examined LN 
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(<15 and ≥ 15) and clinical and pathologic characteristics were compared 
(Table 1).  
In the group with <15 LN retrieved the patients had more comorbidities (95 
versus 80,2%, p=0,024) and, although not statistically significant (p=0,077), it 
was observed that patients with highest ASA scores (III and IV) had an inferior 
number of LN retrieved. The group with ≥ 15 LN retrieved was significantly (p= 
0,004) associated with more proximal and extensive tumor location (body – 31 
versus 5%, fundus – 1,6 versus 0% and extensive – 3,6 versus 2,5%), while the 
<15 LN retrieved group was related to inferior tumor size (3,338 ± 3,2825 
versus 4,611 ± 2,8768, p=0,001). The group with ≥ 15 LN retrieved correlates 
with more advanced gastric cancers (64,1 versus 42,5%, p=0,014), whereas the 
<15 LN retrieved group was associated with lower N stages (N0 – 72,5 versus 
49,6% and N1 – 17,5 versus 15,7%, p=0,031), pathological stage I (70 versus 
41,1%, p=0,003) and less cases of lymphatic permeation and perineural 
invasion (34,2 versus 59,5%, p=0,005 and 21,1 versus 39,9%, p=0,03 
respectively). In what concerns therapeutic approach, in the group with ≥ 15 LN 
retrieved more total gastrectomies (42,3 versus 12,5%, p<0,001) and more D2 
lymphadenectomies (38,3 versus 22,5%, p=0,016) were performed. In fact, in 
91,3% of D2 lymphadenectomies more than or equal to 15 LN were harvested. 
Patients with ≥15 LN harvested did not present significant differences in short 
and long-term complications when compared to patients with <15 LN retrieved 
(Table 2). 
Related to perioperative outcomes (Table 2), though not statistically significant, 
the surgery duration was superior in the group with ≥ 15 LN retrieved (229,52 ± 
51,991 versus 208,8 ± 72,006, p= 0,087). 
Both groups presented similar oncological outcomes (Table 2)., except for the 
number of LN invaded which was significantly higher in the group with ≥ 15 LN 
retrieved (4,04 ± 6,996 versus 0,75 ± 1,765, p=0,001). 
 
Survival analysis  
Overall survival (OS) 
11 
	
Analysis of the effect of the number of LN retrieved 
There was not an association (crude HR 0,986, 95% CI 0,971 – 1,001, p=0,072) 
between the number of LN retrieved and the OS. But when OS was adjusted to 
pathological stage, type of cancer (EGC versus AGC) and N stage, there was 
statistically significant association with the number of LN harvested (HR 0,97. 
95% CI 0,954 – 0,986, p<0,001; HR 0,976, 95% CI 0,961 – 0,992, p=0,003; and 
HR 0,981, 95% CI 0,966 – 0,996, p=0,015, respectively) (Table 3). 
 
Comparative analysis < 15 LN versus ≥15 LN retrieved  
The OS of patients with ≥15 LN retrieved was better than those with < 15 LN, 
but this difference was not statistically significant (p=0,124). When OS curves 
were adjusted to pathological stage (Table 3), the differences were statistically 
significant (HR 0,436, 95% CI 0,262 – 0,727, p=0,001). According to the KM 
curves, these differences were observed in pathological stage I (p<0,001), but 
not in stages II and III (Figure 5). When adjusted to the type of cancer (Table 
3), the OS curves were statistically significant (HR 0,532, 95% CI 0,324 – 0,875, 
p=0,013). According to the KM curves (Figure 6), these differences were 
observed in early gastric cancer (p<0,001). The OS curves were statistically 
significant (HR 0,535, 95% CI 0,324 – 0,883, p=0,014) when adjusted to the N 
stage (Table 3). According to the KM curves (Figure 6), these differences were 
observed in pN- tumors (p=0,002). 
 
Comparative analysis < 15 LN versus 15 - 29 LN versus ≥30 LN retrieved 
The OS of patients with 15 to 29 LN retrieved and with ≥30 LN retrieved was not 
statistically better than that of patients with <15 LN retrieved (p=0,65 and 
p=0,21). Although, when adjusted to pathological stage (Table 3) the 
differences were statistically significant in both groups (HR 0,56, 95% CI 0,33 – 
0,95, p0,032 and HR 0,306, 95% CI 0,172 – 0,544, p<0,001, respectively). 
According to the KM curves, these differences were observed in pathological 
stage I (p=0,001) and III (p=0,032), but not in pathological stage II (Figure 7). 
When adjusted to the type of cancer (Table 3), the OS curves were statistically 
significant in the group with ≥30 LN retrieved (HR 0,401, 95% CI 0,229 – 0,699, 
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p=0,001), when compared to the <15 LN group. According to the KM curves 
(Figure 8), these differences were observed in early tumors (p=0,001). The OS 
curves adjusted to the N stage (Table 3) were statistically significant (HR 0,42, 
95% CI 0,24 – 0,736, p=0,002) in the group of patients with ≥30 LN retrieved 
when compared to the <15 LN group. According to the KM curves (Figure 8), 
these differences were observed in pN- tumors (p=0,003). 
 
Disease specific survival (DSS) 
Analysis of the effect of the number of LN retrieved 
There was not an association (crude HR 1,005, 95% CI 0,986 – 1,025, p=0,585) 
between the number of LN retrieved and the DSS. When DSS was adjusted to 
pathological stage the difference was statistically significant (adjusted HR 
0,977, 95% CI 0,956 – 0,999, p=0,039). However, when DSS was adjusted to 
the type of cancer and N stage there was no significant differences (p=0,479 
and p=0,712) (Table 3). 
 
Comparative analysis < 15 LN versus ≥15 LN retrieved  
The DSS of patients with ≥15 LN retrieved was not significantly different 
(p=0,824) than that of patients with <15 LN retrieved (Table 3). When DSS 
curves were adjusted to pathological stage the differences were statistically 
significant in pathological stage II (p=0,012) (Figure 9). When adjusted to the 
type of cancer and N stage (Table 3), the DSS curves were not statistically 
significant (p=0,462 and p=0,341) (Figure 10). 
 
Comparative analysis < 15 LN versus 15 - 29 LN versus ≥30 LN retrieved 
The DSS of patients with 15 to 29 LN retrieved and with ≥30 LN retrieved was 
not statistically better than that of patients with < 15 LN retrieved (p=0,416 and 
p=0,227) (Table 3). Although, when adjusted to pathological stage the 
difference was significant (p=0,027) in the group with ≥30 LN retrieved, when 
compared to the <15 LN group. According to the KM curves (Figure 11), these 
differences were observed in pathological stage II (p=0,027). When adjusted to 
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the type of cancer and N stage (Table 3), the DSS curves were not statistically 
significant in both groups (Figure 12). 
 
Disease free survival (DFS) 
Analysis of the effect of the number of LN retrieved  
There was not an association (crude HR 1,005, 95% CI 0,988 – 1,023, p=0,566) 
between the number of LN retrieved and the DFS. When DFS was adjusted to 
pathological stage the difference was statistically significant (p=0,043). 
Nevertheless, when DFS was adjusted to the type of cancer and N stage there 
was no significant differences (p=0,451 and p=0,61) (Table 3). 
 
Comparative analysis < 15 LN versus ≥15 LN retrieved  
The DFS of patients with ≥15 LN retrieved was not significantly different 
(p=0,683) than that of patients with <15 LN retrieved (Table 3). When DFS 
curves were adjusted to pathological stage the differences were statistically 
significant in pathological stage II (p=0,002) (Figure 13). When adjusted to the 
type of cancer and N stage (Table 3), the DFS curves (Figure 14) were not 
statistically significant (p=0,488 and p=0,344). 
 
Comparative analysis < 15 LN versus 15 - 29 LN versus ≥30 LN retrieved 
The DFS of patients with 15 to 29 LN retrieved and with ≥30 LN retrieved was 
not statistically better than that of patients with less than 15 LN retrieved 
(p=0,649 and p=0,657) (Table 3). Although, when adjusted to pathological 
stage the difference was significant in the group with ≥30 LN retrieved in 
pathological stage II (p=0,002) (Figure 15). When adjusted to the type of 
cancer and N stage (Table 3), the DFS curves were not statistically significant 
in both groups (Figure 16). 
 
Impact of the number of LN retrieved in surgery duration and morbidity 
There was a significant association between the number of LN retrieved and the 
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surgery duration (standardized beta coefficient 0,148, 95% CI 0,141 – 1,134, 
p=0,012), but the number of LN retrieved only explains 2,2% of the surgery 
duration (R2=0,022). In fact, each LN retrieved increased the surgery duration in 
0,148 minutes (Figure 17). 
In terms of morbidity, the number of LN harvested was not significantly 
(p=0,053) associated with the presence of complications (Table 4). 
 
Predictors of the number of LN retrieved 
In univariate analysis (Table 5), the following variables were predictors of the 
number of LN harvested: age (p<0,001), type of resection (p<0,001), type of 
lymphadenectomy (p<0,001), tumor location (p<0,001), tumor size (p=0,003), 
type of tumor [EGC vs advanced] (p=0,015), pN (p=0,037), number of LN 
invaded (p<0,001) and pStage (p<0,001). According to the multivariate analysis 
(R2 0,261 for this model), the independent predictors were: type of resection 
(p<0,001), type of lymphadenectomy (p<0,001), tumor location (p=0,013) and 
number of LN invaded (p<0,001) (Table 5).  
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Discussion 
Gastric cancer is still a global and important concern nowadays, being the 
second leading cause of cancer-related death in the world. The notion that the 
number of lymph nodes harvested acts as an important prognostic factor in 
gastric cancer is not recent and has been previously described in multiple 
studies [7, 11-14]. It is also known that various factors can influence the number 
of lymph nodes retrieved in gastric cancer patients, such as surgical technique, 
extent of surgery, extent of pathologic examination of the specimen and 
individual characteristics like fat volume and innate number of lymph nodes                                                                                                                                                                                                                                         
[5, 15].  
Currently the cut-off established by AJCC for adequate staging is 15 lymph 
nodes, however this seems not always appropriate to increase survival, reduce 
recurrence and prevent stage migration. Numerous studies have suggested 
different cut-off values, but the ideal one remains unclear.  
Data et al [16] observed that harvesting less than 15 LN was independently 
related to worst OS. Ling et al [17] demonstrated that patients with more than or 
equal to 20 LN retrieved had an improvement on the survival rate when 
compared with patients with less than 20 lymph nodes. Shen et al [13] showed 
that patients with more than 30 lymph nodes resected had significantly better 
OS and progression free survival (PFS) than those with less than or equal to 14 
lymph nodes retrieved. However, there was no significant difference in OS and 
PFS between patients with less than 14 and 15 to 29 lymph nodes retrieved. 
This study also revealed that harvesting more than 30 lymph nodes was 
associated with better OS than harvesting 15 to 29 lymph nodes, suggesting 
that dissecting a superior number of lymph nodes probably contributes to 
improve survival in gastric cancer patients. Our data showed that, when the 
number of lymph nodes retrieved was analyzed as a continuous variable and 
adjusted to pathological stage, patients with a superior number of lymph nodes 
harvested presented with a better survival and reduce disease recurrence. 
Harvesting more than or equal to 15 lymph nodes had positive effects on the 
OS of gastric cancer patients with pathological stage I, early gastric cancer and 
negative N stage (pN-), but not in more advanced stage patients. Moreover, 
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retrieving more than or equal to 15 lymph nodes contributed to improvements in 
DSS and DFS of patients in pathological stage II. This information is congruent 
with other studies. Son et al [17] concluded that the outcomes of T1N0 stage 
patients in whom the number of examined lymph nodes was less than 15 were 
worse than patients in whom more than 15 lymph nodes were examined. Zhao 
et al [6] revealed that a lymphadenectomy with dissection of more than 15 
lymph nodes might improve the long-term survival of patients with pT1N0 
gastric cancer. All together this data suggests that patients with less advanced 
stages of gastric cancer may benefit from a more extensive lymphadenectomy 
in terms of survival. The cause for this association is not clear but it can be due 
to superior loco-regional disease control. As the number of lymph nodes 
harvested increases, the probability of retrieving positive lymph nodes or lymph 
nodes with micrometastases rises, resulting in a more accurate N stage 
classification and higher survival rates [18, 19]. However, these findings were 
not showed in other studies. Shen et al [13] concluded that the number of lymph 
nodes harvested had no effect on both OS and PFS of gastric cancer patients 
with pathological stage I and II, N0, T1 and T2. Instead they find that the higher 
the number of lymph nodes retrieved, the better was the OS and PFS in T3 to 
T4 gastric cancer, N+ and III to IV stages and, specifically when more than or 
equal to 15 lymph nodes were harvested, the OS and PFS were significantly 
better in N+ patients. Deng et al [12] also demonstrated that harvesting more 
than or equal to 15 lymph nodes was associated with better prognosis of N+ 
gastric cancer. Gholami et al [7] showed that survival after gastrectomy was 
improved when 16 lymph nodes or more were removed in all pathological 
stages, except advanced stage (III-B e III-C or N3). 
In this study, we also showed that when more than 30 lymph nodes were 
retrieved the OS of gastric cancer patients was significantly better not only in 
stage I, early gastric cancer and N-, but also in stage III. Furthermore, 
harvesting more than 30 lymph nodes was associated with better DSS and DFS 
in pathological stage II gastric cancer patients. The findings are similar to those 
of other studies. Siewert et al [20] determined that harvesting more than 25 
lymph nodes had a significant and independent effect on survival in patients 
with stage II tumors. Shen et al [13] demonstrated that retrieving more than 30 
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lymph nodes was associated with better OS than harvesting 15 to 29 lymph 
nodes and is highly recommended for patients with advanced stages (T3 to T4, 
N+ and III to IV stages). Based on our results it seems that in pathological stage 
III tumors the established cut-off of 15 lymph nodes may not be appropriate. 
Our data suggests that lymphadenectomy should be individually designed for 
each patient according to tumor stage. 
In the past, many western studies reported that D2 lymphadenectomy was 
associated with higher rates of perioperative mortality and surgical complication 
[21-23]. However, more recent western studies demonstrated that D1 and D2 
lymphadenectomy have similar perioperative mortality [20, 24, 25]. Furthermore 
Gholami et al [7] revealed that perioperative mortality between patients with 7 to 
15 lymph nodes and more than 16 lymph nodes retrieved was similar (4,7% 
versus 3,1% respectively). These results support our findings, since we showed 
that harvesting more lymph nodes was not associated with higher rates of post-
surgical complications. 
In conclusion, our results suggest that the number of lymph nodes harvested 
has prognostic implication on gastric cancer patients survival and that retrieving 
a higher number of lymph nodes is not associated with more complications. 
Therefore, lymphadenectomy extension should be individually designed for 
each patient according to tumor stage. 
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< 15 LN retrieved (n=40)  ≥15 LN retrieved (n=248) Total P value
Age at surgery (years), mean ± SD 69,93 ± 10,885 66,46 ± 12,39 66,94 ± 12,234 ns (0,105)*
Gender, n (%) ns (0,864)
Male 24 (60) 143 (57,7) 167 (58)
Female 16(40) 105 (42,3) 121 (42)
BMI, mean ± SD 26,196 ± 3,0304 25,805 ± 3,9092 25,852 ± 3,8102 ns (0,509)*
Comorbidities presence, n (%) 38 (95) 199 (80,2) 237 (82,3) 0,024
ASA score, n (%) ns (0,077)
I 2 (5) 38 (15,3) 40 (13,9)
II 19 (47,5) 138 (55,6) 157 (54,5)
III 18 (45) 69 (27,8) 87 (30,2)
IV 1 (2,5) 3 (1,2) 4 (1,4)
Tumor location, n (%) 0,004
Antrum 37 (92,5) 158 (63,7) 195 (67,7)
Body 2 (5) 77 (31) 79 (27,4)
Fundus 0 (0) 4 (1,6) 4 (1,4)
Extensive 1 (2,5) 9 (3,6) 10 (3,5)
Tumor size (cm), mean ± SD 3,338 ± 3,2825 4,611 ± 2,8768 4,444 ± 2,9584 0,001**
Mascroscopic appearance, n (%) ns (0,095)
Fungating 11 (33,3) 34 (14,5) 45 (16,9)
Ulcerated 9 (27,3) 67 (28,6) 76 (28,5)
Infiltrative 2 (6,1) 29 (12,4) 31 (11,6)
Ulcero-fungating 3 (9,1) 29 (12,4) 32 (12)
Ulcero-infiltrative 8 (24,2) 75 (32,1) 83 (31,1)
Histologic type (Laurén), n (%) ns (0,121)
Intestinal 24 (63,2) 102 (42,1) 126 (45)
Diffuse 2 (5,3) 35 (14,5) 37 (13,2)
Unclassified of solid structure 0 (0) 8 (3,3) 8 (2,9)
Unclassified of mixed structure 9 (23,7) 68 (28,1) 77 (27,5)
Unclassified SOE 3 (7,9) 29 (12) 32 (11,4)
Growth pattern (Ming), n (%) ns (0,931)
Expansive 7 (18,9) 51 (21,1) 58 (20,8)
Infiltrative 28 (75,7) 176 (72,7) 204 (73,1)
Unclassified 2 (5,4) 15 (6,2) 17 (6,1)
pT (7th ed, 2010), n (%) ns (0,120)
pTis 1 (2,5) 5 (2) 6 (2,1)
pT1a 10 (25) 42 (16,9) 52 (18,1)
pT1b 11 (27,5) 41 (16,5) 52 (18,1)
pT2 6 (15) 31 (12,5) 37 (12,8)
pT3 5 (12,5) 82 (33,1) 87 (30,2)
pT4a 6 (15) 42 (16,9) 48 (16,7)
pT4b 0 (0) 4 (1,6) 4 (1,4)
pTx 1 (2,5) 1 (0,4) 2 (0,7)
Type of tumor, n (%) 0,014
Early gastric cancer 23 (57,5) 89 (35,9) 112 (38,9)
Advanced gastric cancer 17 (42,5) 159 (64,1) 176 (61,1)
pN (7th ed, 2010), n (%) 0,031
N0 29 (72,5) 123 (49,6) 152 (52,8)
N1 7 (17,5) 39 (15,7) 46 (16)
N2 2 (5) 28 (11,3) 30 (10,4)
N3a 2 (5) 39 (15,7) 41 (14,2)
N3b 0 (0) 19 (7,7) 19 (6,6)
LN ratio, n (%) ns (0,074)
≤ 0,2 35 (87,5) 184 (74,2) 219 (76,0)
> 0,2 5 (12,5) 64 (25,8) 69 (24)
Pathological stage, n (%) 0,003
I 28 (70) 102 (41,1) 130 (45,1)
II 6 (15) 61 (24,6) 67 (23,3)
III 6 (15) 85 (34,3) 91 (31,6)
Lymphatic permeation, n (%) 13 (34,2) 144 (59,5) 157 (56,1) 0,005
Venous invasion, n (%) 14 (36,8) 113 (46,5) 127 (45,2) ns (0,297)
Perineural invasion, n (%) 8 (21,1) 97 (39,9) 105 (37,4) 0,03
Clinico-pathological profile
Comparative analysis <15 LN versus ≥15 LN retrieved: Baseline characteristics
Demographics
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Table 1: Comparative analysis <15 LN versus ≥15 LN retrieved: Baseline 
characteristics (n=288). 
SD, standard deviation; ns, non-significant; BMI, body mass index; ASA, 
American Society of Anesthesiologists. 
*Student’s t-test; ** Non-parametric test Mann Whitney U. 
Significant p values (<0,05) and strong trend p values (<0,1) are highlighted in 
bold. 
 
  
Surgery approach ns (0,651)
Open 23 (57,5) 134 (54) 157 (54,5)
Laparoscopic 15 (37,5) 107 (43,1) 122 (42,4)
Converted 2 (5) 7 (2,8) 9 (3,1)
Type of resection, n (%) <0,001
Total gastrectomy 5 (12,5) 105 (42,3) 110 (38,2)
Billroth II Distal Gastrectomy 34 (85) 124 (50) 158 (54,9)
Roux-en-Y Distal Gastrectomy 1 (2,5) 19 (7,7) 20 (6,9)
Type of lymphadenectomy, n (%) 0,016
D1 17 (42,5) 55 (22,2) 72 (25)
D1+ 14 (35) 98 (39,5) 112 (38,9)
D2 9 (22,5) 95 (38,3) 104 (36,1)
Neoadjuvant therapy, n (%) 5 (12,5) 21 (8,5) 26 (9,0) ns (0,38)
Therapeutic approach
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< 15 LN retrieved (n=40)  ≥15 LN retrieved (n=248) Total P  value
Morbidity, n(%) 11 (27,5) 50 (20,2) 61 (21,2) ns (0,3)
Anastomotic leakage 3 (7,5) 5 (2) 8 (2,8) ns (0,085)
Clavien classification, n(%) ns (0,448)
I 0 (0) 1(2) 1 (1,6)
II 7 (58,3) 20 (40) 27 (43,5)
IIIa 0 (0) 7 (14) 7 (11,3)
IIIb 1 (8,3) 12 (24) 13 (21)
IVa 0 (0) 1 (2) 1 (1,6)
IVb 0 (0) 1 (2) 1 (1,6)
V 4 (33,3) 8 (16) 12 (19,4)
Clavien ≥ IIIa (need for intervention) 5 (45,5) 30 (58,8) 35 (56,5)
Post-operative mortality, n(%) 4 (10) 8 (3,2) 12 (4,2) ns (0,069)
Reintervention, n(%) 4 (10) 21 (8,5) 25 (8,7) ns (0,762)
Readmission, n(%) 2 (5) 17 (6,9) 19 (6,6) ns (1)
Transfusion presence, n(%) 4 (11,1) 33 (15,9) 37 (15,2) ns (0,617)
Long-term complications, n(%) 0 (0) 16 (6,5) 16 (5,6) ns (0,14)
Reintervention, n(%) 0 (0) 5 (2) 5 (1,7) ns (1)
Surgery duration (minutes), mean ± SD 208,8 ± 72,006 229,52 ± 51,991 226,64 ± 55,520 ns (0,087)**
Post-operative LOS (days), mean ± SD 13,25 ± 17,137 10,92 ± 16,408 11,24 ± 16,501 ns (0,414)*
R classification, n (%) ns (1)
R0 39 (97,5) 239 (96,4) 278 (96,5)
R1 1 (2,5) 9 (3,6) 10 (3,5)
Proximal margin distance (cm), mean ± SD 4,568 ± 2,6585 5,410 ± 3,0761 5,296 ± 3,0322 ns (0,124)*
Distal margin distance (cm), mean ± SD 3,689 ± 2,7389 4,4 ± 6,996 4,304 ± 3,1457 ns (0,238)*
Lymph nodes invaded, mean ± SD 0,75 ± 1,765 4,04 ± 6,996 3,59 ± 6,622 0,001*
Recurrence presence, n (%) 7 (17,5) 62 (25) 69 (24) ns (0,424)
Recurrence type, n (%) ns (0,38)
Local 0 (0) 9 (16,1) 9 (14,5)
Ganglionar 0 (0) 5 (8,9) 5 (8,1)
Distant metastases 6 (100) 42 (75) 48 (77,4)
Outcomes
Perioperative outcomes
Oncological related outcomes
Short-term complications
Long-term complications
 
Table 2: Comparative analysis <15 LN versus ≥15 LN retrieved: Outcomes 
(n=288). 
SD, standard deviation; ns, non-significant; LOS, length of stay; LN, lymph 
node. 
*Non-parametric test Mann Whitney U; **Welch's t-test. 
Significant p values (<0,05) and strong trend p values (<0,1) are highlighted in 
bold. 
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Table 3: Survival analysis: Cox regression 
 I. Crude and adjusted HR for pathological stage 
 II. Adjusted HR for EGC and pN 
HR, hazard ratio; CI, confidence interval; EGC, early gastric cancer. 
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Table 4: Impact of the number of LN retrieved in morbidity: Logistic regression 
OR, odds ratio; CI, confidence interval. 
 
  
Beta coefficient Crude OR 95% CI P  value
Number of LN retrieved -0,024 0,976 0,953 - 1 ns (0,053)
Complications
Impact of the number of LN retrieved in morbidity: Logistic regression
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R square for the model of the multivariate analysis: 0,261 
	
Table 5: Predictors of number of LN retrieved: Uni and multivariate analysis by 
linear regression 
 
 
  
R square P  value P  value
Multivariate analysis
Age 0,053 <0,001
Type of resection 0,11 <0,001 <0,001
Type of lymphadenectomy 0,097 <0,001 <0,001
Tumor location 0,053 <0,001 0,013
Tumor size 0,032 0,003
Type of tumor (EGC vs Advanced) 0,021 0,015
pN (7th ed, 2010) 0,015 0,037
Type of tumor (EGC vs Advanced) 0,021 0,015
Number LN invaded 0,083 <0,001 <0,001
Pathological stage 0,042 <0,001
Univariate analysis
Predictors of number of LN retrieved: Linear regression
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Initial population (n= 476) 
January 2010 – December 2015 
Patients treated in Upper GI Surgery Unit, Centro Hospitalar 
de São João – Faculty of Medicine, University of Porto 
Exclusion criteria (n=180) 
55 - Non resectional surgery 
44 - Palliative resection  
37 - Pathological stage IV   
20 - Completion gastrectomy 
8 - Histologic type other than adenocarcinoma 
8 - Atypical gastrectomy 
6 - Prophylactic gastrectomy 
2 - R2 resection 
 
Lost follow-up (n=8) 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 1:  Flow chart of the study design 
  
Cases included (n=288) 
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Figure 2: Type of lymphadenectomy according to the type of resection (total or distal 
gastrectomy) in Japanese Gastric Cancer Association. Japanese gastric cancer 
treatment guidelines (ver.3). Gastric Cancer- 2011 Jun; 14(2): 113-23. 
Total gastrectomy: 
D0: Lymphadenectomy less than D1; 
D1: Nos. 1–7 (highlighted in blue); 
D1+: D1 plus Nos. 8a, 9, 11p (highlighted in yellow); 
D2: D1+ plus Nos. 10, 11d, 12a (highlighted in red). 
 
Distal gastrectomy: 
D0: Lymphadenectomy less than D1; 
D1: Nos. 1, 3, 4sb, 4d, 5, 6, 7 (highlighted in blue); 
D1+: D1 plus Nos. 8a, 9 (highlighted in yellow); 
D2: D1+ plus Nos. 11p, 12a (highlighted in red). 
  
Total gastrectomy 
Distal gastrectomy 
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Figure 3:  Box plot of the number of lymph nodes retrieved in patients with minimum number 
for adequate staging (≥15 LN) 
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Log rank, p<0,001 
Log rank, p<0,001 
Log rank, p<0,001 
A 
B 
C 
Figure 4:  OS of gastric cancer patients according to (A) pathological 
stage, (B) type of gastric cancer (EGC versus AGC) and (C) pN stage. 
OS, overall survival; EGC, early gastric cancer; AGC, advanced gastric 
cancer. 
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Log rank, p=0,537 
Log rank, p=0,119 Log rank, p<0,001 
Log rank, p=0,365 
A B 
C D 
Figure 5:  Impact of the number of lymph nodes retrieved in OS of gastric cancer patients (A) 
and adjusted to tumor stage. (B) OS of stage I, (C) OS of stage II and (D) OS of stage III.  
OS, overall survival. 
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Log rank, p<0,001 
Log rank, p=0,002 Log rank, p=0,537 
Log rank, p=0,401 
A B 
C D 
Figure 6:  Impact of the number of lymph nodes retrieved in OS of gastric cancer patients 
according to the type of tumor and N stage. (A) OS of EGC, (B) OS of AGC, (C) OS of N- and 
(D) OS of N+. 
OS, overall survival, EGC, early gastric cancer, AGC, advanced gastric cancer.  
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Log rank, p=0,057 Log rank, p=0,001 
Log rank, p=0,33 Log rank, p=0,032 
A B 
C D 
Figure 7:  Impact of the number of lymph nodes retrieved in OS of gastric cancer patients (A) 
and adjusted to tumor stage. (B) OS of stage I, (C) OS of stage II and (D) OS of stage III.  
OS, overall survival. 
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Log rank, p=0,001 Log rank, p=0,6 
Log rank, p=0,003 Log rank, p=0,254 
A B 
C D 
Figure 8:  Impact of the number of lymph nodes retrieved in OS of gastric cancer patients 
according to the type of tumor and N stage. (A) OS of EGC, (B) OS of AGC, (C) OS of N- and 
(D) OS of N+. 
OS, overall survival, EGC, early gastric cancer, AGC, advanced gastric cancer.  
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Log rank, p=0,823 Log rank, p=0,645 
Log rank, p=0,012 Log rank, p=0,361 
A B 
C D 
Figure 9:  Impact of the number of lymph nodes retrieved in DSS of gastric cancer patients (A) 
and adjusted to tumor stage. (B) DSS of stage I, (C) DSS of stage II and (D) DSS of stage III.  
DSS, disease specific survival. 
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Log rank, p=0,661 Log rank, p=0,406 
Log rank, p=0,491 Log rank, p=0,534 
A B 
C D 
Figure 10:  Impact of the number of lymph nodes retrieved in DSS of gastric cancer patients 
according to the type of tumor and N stage. (A) DSS of EGC, (B) DSS of AGC, (C) DSS of N- 
and (D) DSS of N+. 
DSS, disease specific survival, EGC, early gastric cancer, AGC, advanced gastric cancer.  
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Log rank, p=0,97 Log rank, p=0,574 
Log rank, p=0,027 Log rank, p=0,45 
A B 
C D 
Figure 11:  Impact of the number of lymph nodes retrieved in DSS of gastric cancer patients (A) 
and adjusted to tumor stage. (B) DSS of stage I, (C) DSS of stage II and (D) DSS of stage III.  
DSS, disease specific survival. 
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Log rank, p=0,585 Log rank, p=0,633 
Log rank, p=0,329 Log rank, p=0,785 
A B 
C D 
Figure 12:  Impact of the number of lymph nodes retrieved in DSS of gastric cancer patients 
according to the type of tumor and N stage. (A) DSS of EGC, (B) DSS of AGC, (C) DSS of N- 
and (D) DSS of N+. 
DSS, disease specific survival, EGC, early gastric cancer, AGC, advanced gastric cancer.  
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Log rank, p=0,635 Log rank, p=0,505 
Log rank, p=0,002 Log rank, p=0,794 
A B 
C D 
Figure 13:  Impact of the number of lymph nodes retrieved in DFS of gastric cancer patients (A) 
and adjusted to tumor stage. (B) DFS of stage I, (C) DFS of stage II and (D) DFS of stage III.  
DFS, disease free survival. 
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Log rank, p=0,423 Log rank, p=0,338 
Log rank, p=0,54 Log rank, p=0,483 
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C D 
Figure 14:  Impact of the number of lymph nodes retrieved in DFS of gastric cancer patients 
according to the type of tumor and N stage. (A) DFS of EGC, (B) DFS of AGC, (C) DFS of N- 
and (D) DFS of N+. 
DFS, disease free survival, EGC, early gastric cancer, AGC, advanced gastric cancer.  
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Log rank, p=0,893 Log rank, p=0,332 
Log rank, p=0,002 Log rank, p=0,898 
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Figure 15:  Impact of the number of lymph nodes retrieved in DFS of gastric cancer patients (A) 
and adjusted to tumor stage. (B) DFS of stage I, (C) DFS of stage II and (D) DFS of stage III.  
DFS, disease free survival. 
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Log rank, p=0,196 Log rank, p=0,594 
Log rank, p=0,35 Log rank, p=0,779 
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C D 
Figure 16:  Impact of the number of lymph nodes retrieved in DFS of gastric cancer patients 
according to the type of tumor and N stage. (A) DFS of EGC, (B) DFS of AGC, (C) DFS of N- 
and (D) DFS of N+. 
DFS, disease free survival, EGC, early gastric cancer, AGC, advanced gastric cancer.  
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Figure	17:		Impact	of	the	number	of	LN	retrieved	in	surgery	duration	
Red	line,	fit	line	of	linear	regression	model	
Blue	lines,	95%	CI	for	the	mean	of	surgery	duration	
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